article · Journal of Medical Economics

The cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab

Bernadette Poellinger
A.H. Abdelaziz
Burak Ersoy
Min Huang
Amin Haiderali
Loay Kassem
Gihan Hamdy Elsisi

20241 citationOpen accessAin Shams University

Abstract

In Egypt, pembrolizumab + chemotherapy/pembrolizumab is a cost-effective treatment for high-risk, early-stage, triple-negative breast cancer when considering health-related quality-of-life and years of life gained.

Research topics

Cancer Immunotherapy and Biomarkers
Breast Cancer Treatment Studies
Economic and Financial Impacts of Cancer

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1080/13696998.2024.2441073

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.